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ABSTRACT
Knowles, Kellen Alexander. M.S.B.M.E., Purdue University, August 2013. Adipose
Stromal Cells Enhance Keratinocyte Survival and Migration in vitro, and Graft
Revascularization In Mouse Wound Healing Model. Major Professor: Keith L.
March.
In the US, more than 1 million burn injuries are reported annually. About 45,000
injuries due to fires and burns result in hospitalization and ten percent of these result
in death every year. Advances in burn treatment have led to a reduction in mortality
rate over the last decades. Since more patients are surviving the initial resuscitation
phase even with very large areas of skin being burned away, wound care has become
increasingly important to ensure continued patient survival and improvement.
While currently a common treatment for third degree burn wounds, skin grafts
have several drawbacks. The availability of donor sites for autografts may be limited,
especially in incidences of extensive skin loss. The rejection associated with the
use of allografts and xenografts may render them inadequate or undesirable. Even
if a suitable graft is found, poor retention due to infection, hematoma, and low
vascularity at the recipient site are other drawbacks associated with the use of skin
grafts as a primary treatment for severe burn wounds. As such, research has been
done into alternative treatments, which include but are not limited to artificial skin,
cell therapy, and growth factor application.
We propose the delivery of adipose derived stem cells (ASC) in combination with
endothelial progenitor cells (EC) via Integra Dermal Regenerative Template (DRT) to
promote faster graft vascularization and thus faster healing of wounds. Integra DRT
is an acellular skin substitute that consists of a dermal layer composed of bovine col-
lagen and chondroitin-6-sulfate glycosaminoglycan, and an ”epidermal” layer, which
consists of silicone polymer. This silicone layer is removed after the collagen matrix
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is adequately vascularized (usually takes 2-3 weeks), and then a thin layer autograft
is applied to the top of the neo-dermis. ASC are derived from the stromal-vascular
fraction (SVF) of adipose tissue and are a readily available, pluripotent, mesenchy-
mal cell known to promote angiogenesis. They are being explored as a treatment for
a myriad of diseases and conditions, including wound healing. In combination with
ECs, they form stable microvessel networks in vitro and in vivo.
In our work, we found that ASC+EC form stable microvessel networks when
cultured on Integra DRT. Also, ASC and ASC+EC conditioned media promoted
both survival and migration of human epidermal keratinocytes compared to control
medium. In a full thickness wound healing model, using healthy NSG mice, the
ASC+EC case showed a significantly higher rate of wound closure compared to con-
trol. Based on best linear unbiased estimates (BLUE), the difference between the
healing rates of ASC alone treatment and the Control treatment group is -0.45 +/-
0.22 mm2/day (p=0.041), which is not less than 0.025 and thus not statistically sig-
nificant (Bonferroni Adjusted). However, the BLUE for the difference between the
ASC+EC group and the Control group healing rates is -0.55 +/- 0.28 mm2/day (p
= 0.017 < 0.025, Bonferroni Adjusted), which is statistically significant. Histology
revealed a significantly higher number of vessels compared to control in both ASC
alone and ASC+EC case. CD31 staining revealed the presence of human vessels in
ASC+EC treatment scaffolds.
We conclude that the combination of ASC and EC can be used to accelerate
healing of full-thickness wounds when delivered to site of the wound via Integra. This
result is especially compelling due to the fact that the mice used were all healthy.
Thus our treatment shows an improvement in healing rate even compared to normal
wound healing.
11. INTRODUCTION
Wound healing therapy dates back as far as 2000 B.C. with the Sumerians who
applied a poultice-like material to wounds to aid in healing [1]. Around 1500 BC
the ancient Egyptians and Grecians used honey, lint and animal grease as topical
treatments for wounds [1, 2]. The honey served as an antimicrobial agent. The lint
was an absorbent, and the grease served as a barrier to pathogens [1, 2]. Today,
with such novel advancements as bioengineered skin substitutes, negative pressure
therapy, hyperbaric oxygen therapy, and stem cell based therapies (to name a few),
we have come a long way [3, 4]. However, many of the basic principles of wound
healing treatments remain the same.
In this paper we focus on the combination of adult stem cells with bioengineered
skin substitutes to aid in treatment of third degree burn wounds.
1.1 Structure of Skin
The skin is constantly exposed to stresses from the surrounding environment (me-
chanical, thermal, microbiological, chemical, etc.) [5]. Mammalian skin functions
to protect underlying tissues on many levels and has thermo- and osmo-regulatory
functions [6]. With such important roles, the skin’s ability to regenerate and heal is
crucial.
Skin consists of an outer epithelium and inner connective tissue layer [5, 7]. The
epithelium, known as the epidermis is avascular. It consists of several layers of ker-
atinocytes, which form a waterproof barrier to protect the underlying tissue and
prevent water loss [5, 7]. Epidermis regenerates readily when injured, provided the
underlying dermis is not affected [5, 7]. The connective tissue layer consists of the
dermis and hypodermis. The collagen-rich dermis is vascularized and contains elastic
2fibers, hair follicles, oil glands, sweat glands, fibroblasts and nerve endings, all of
which help skin fulfill its protective and regulatory roles [7]. The dermis provides the
structural support and strength of the skin [7]. If a wound results in bleeding, this
indicates damage to the dermis [7]. The hypodermis is a fatty layer that provides
support and padding to the skin [5, 7].
1.2 Healing Process
The process of wound healing involves 4 major steps including hemostasis, inflam-
mation, proliferation, and remodeling. These phases are interactive and overlap in the
healing process [8,9]. Hemostasis is marked by vasoconstriction and fibrin clot forma-
tion [8,9]. Platelets adhere to the injured epithelium to help plug the breach in the ves-
sel wall [8,9]. The clot, along with surrounding wound tissue, secrete chemokines that
help initiate the inflammatory response [8–10]. The inflammatory phase is marked
by vasodilation and an increase in vascular permeability. Neutrophils, macrophages,
and lymphocytes are attracted to the wound site [8, 9]. Neutrophils target invading
microbes and cellular debris [8]. Macrophages are a phagocytic cell that clear away
cellular debris, produce various chemokines and growth factors, and play a key role
in initiating the proliferative phase [8, 9, 11]. T-lymphocytes, assist in regulating the
inflammatory phase, and target pathogens via cell-mediated immunity [8].
The proliferative phase is marked by re-epithelialization, angiogenesis, ECM for-
mation, and synthesis of collagen [8]. The remodeling phase, which can last for years,
is characterized by a restoration of normal vascular density, wound contraction, and
ECM remodeling. At each step in the healing process cytokines, chemokines, and
growth factors help direct wound healing events. The goal is the restoration of cellu-
lar structures and tissue layers.
31.3 Burn Wounds
In the US, more than 1 million burn injuries are reported annually [12–14]. About
45,000 injuries due to fires and burns result in hospitalization and ten percent of these
result in death every year [14].
Advances in burn treatment have led to a reduction in mortality rate over the last
decades [14,15]. Since more patients are surviving the initial resuscitation phase even
with very large areas of skin being burned away, wound care has become increasingly
important to ensure continued patient survival and improvement [14,15].
Burn wounds are classified according to the depth of the injury. Superficial wounds
that affect just the epidermis are known as first degree burn wounds and require
no surgical intervention [16]. Second degree burn wounds include damage to the
epidermis and dermis and may need to be debrided, treated with antibiotics and
dressed with a wound dressing [16]. Third degree burn wounds are ones in which
both the epidermis and dermis are damaged or destroyed. In most cases they must
be treated via surgical debridement and skin grafting [16]. With the dermis and
epidermis damaged, the skin has limited ability to regenerate itself and will result in
extensive scarring if left treated [17].
1.3.1 Current Clinical Treatments
Skin grafting is a surgical procedure that involves taking skin from one area of the
body and using it to cover and stimulate healing in the injured portions of skin [18].
Presently, the only effective treatment for severe second degree and third degree burn
wounds is a skin graft or use of artificial skin [16, 18]. In adults, the dermis has
limited ability to regenerate unaided, so deep wounds, if left untreated, will heal
by scar tissue formation or in some cases, not at all [17]. Open wounds are highly
susceptible to infection [16, 19]. The longer the wound is open the longer the risk
remains. If infection does develop, this will lead to an even slower healing and can
cause other complications, including death [16].
4If the graft is taken from the patients own skin it is known as an autograft. If
the available skin on the patient is unsuitable for use as a graft, or if there is an
insufficient amount of skin available for forming the graft, skin can also be used from
another person (allograft) or organism (xenograft). These will only serve as temporary
solutions since the body will eventually reject them. There are several types of skin
grafts [18]:
1. Pinch grafts: quarter inch pieces of skin that are spaced around site of injury.
They eventually grow and spread, making larger and larger islands of new skin.
2. Split-thickness grafts: sheets of mostly superficial and some deep layers of skin
that are used to cover non weight bearing portions of the body.
3. Full-thickness grafts: same as above except composed of deep layers of skin.
Used for weight-bearing and friction prone areas such as feet and joints.
The recipient site is prepared for the skin graft by debridement or removal of dead
and necrotic tissue. Favorable surfaces for skin graft take include briskly bleeding
dermis or glistening fat [18]. If necessary, debridement can be done down to the
muscle layers [18].
1.3.2 Drawbacks and Limitations of Skin Graft Treatments
While currently a common treatment for third degree burn wounds, skin grafts
have several drawbacks. The availability of donor sites for autografts may be limited,
especially in incidences of extensive skin loss [14, 16, 20]. If this is the case, repeated
harvesting is necessary, and this is associated with pain and scarring at the donor
site [14]. The rejection and possible transfer of infection associated with the use of
allografts and xenografts may render them inadequate [20]. Poor graft retention due
to infection, hematoma, and low vascularity at recipient site are other drawbacks
associated with the use of skin grafts as a primary treatment for severe burn wounds
[21]. As such, research has been done into the use of artificial skin substitutes as a
5burn treatment. They are readily available, non-immunogenic, encourage in-growth
of surrounding cells, and can be loaded with specialized cells or growth factors that
stimulate faster healing, prevent fluid loss, and reduce scarring [17,20,21].
1.3.3 Skin Substitutes
Skin substitutes serve as a readily available treatment for burn wounds. They can
be subdivided into three major categories: acellular, cellular and cellular autologous
[20].
Three examples of acellular skin substitutes include Biobrane, Integra and Al-
loderm [14, 20]. Biobrane is a temporary skin substitute, which consists of a ny-
lon mesh and semi-permeable silicone backing. Collagen is chemically linked to the
nylon and silicone matrix, which improves its adherence to the wound bed. The
Biobrane matrix is removed once the wound is healed or when autograft skin be-
comes available [14, 20]. Integra Dermal Regeneration Template consists of a dermal
layer composed of bovine collagen and chondroitin-6-sulfate glycosaminoglycan, and
an ”epidermal” layer, which consists of silicone polymer [14]. The collagen matrix
encourages ingrowth of cells from the wound bed [14]. This repopulation leads to
eventual collagen matrix remodeling [14]. The silicone layer is removed after the col-
lagen matrix is adequately vascularized, and then a thin layer autograft is applied
to the top of the neo-dermis [14, 20]. Alloderm is composed of decellularized human
dermis derived from cadavers [14]. It is treated so that it maintains native dermal
structure, which facilitates cellular ingrowth and remodeling [14,20].
Examples of cellular-based skin substitutes indicated for use in burn treatment
include Transcyte [14,22] and OrCel [14,20]. Transcyte is a temporary wound covering
for burns and is composed of nylon and a silastic membrane [14,20]. Neonatal foreskin-
derived fibroblasts are seeded onto the nylon mesh and allowed 3-6 weeks to produce
extracellular matrix and growth factors. However, in order to prevent an immune
response, the fibroblasts are destroyed before Transcyte is applied to the wound.
6Orcel is a skin graft composed of a type I collagen sponge that contains epidermal
keratinocytes and dermal fibroblasts [14,23]. It is indicated for use in treating donor
sites from which skin grafts are obtained [14,23]. The allogeneic cells serve a purpose
in secreting factors and stimulating the healing process, but are eventually destroyed
by the host [23].
The skin substitutes discussed above have the advantage of being readily available.
However, they will eventually require replacement by the patient’s own cells [14].
Their benefit is that they can be used to help facilitate wound closure while autologous
cells are prepared for grafting [14].
Epicel, also known as cultured epidermal autograft (CEA) is an example of a
cellular autologous skin substitute. It consists of sheets of autologous keratinocytes
that were originally obtained from a skin biopsy taken from the patient, that has
been expanded in culture [14]. The cells are seeded onto a petrolatum gauze backing
that is removed about 1 week after graft is applied to the wound [14]. Epicel has
been useful in treating patients with a total burn surface area (TBSA) of 60% or
greater [14, 24]. Epicel has the advantage of being autologous, compared to other
treatments, however, disadvantages include mechanical fragility, and obvious time
needed for cell expansion (16-21 days) [14, 24,25].
One of the most important factors in successful wound closure is timely and ef-
ficient vascularization of the skin graft. Poor graft revascularization is one of the
highest contributing factors to graft failure [26]. Combining an acellular skin graft
with a readily available, autologous cell or combination of cells that promote rapid
and robust vascularization is one possible approach to addressing this issue. Adipose
Stromal Cells (ASCs) are one such cell that have been shown to stabilize formation
of vascular networks formed by endothelial cells [27].
71.4 Description of Adipose Stromal Cell Biology
Adipose Stromal Cells (ASC) are a population of pluripotent, mesenchymal stem
cells, derived from the stromal-vascular fraction of adipose tissue. Traktuev, et.al,
showed that the majority of CD34+ cells in the fat tissue were associated with vessels
in the tissue [28]. While some CD34+ cells co-expressed CD31 (marker for endothe-
lial cells), the predominant population is CD31-. The perivascular position of this
latter population, suggests their pericytic function [28]. Upon isolation, it was found
that the majority of CD34+/CD31-/CD45-/CD144- cells defined as ASC, also ex-
press mesenchymal cell markers, such as CD10, CD13, and CD90, as well as pericyte
markers - CD140a, and CD140b (PDGF receptor-α and -β, respectively) [28].
It has been shown that ASC possess high plasticity and are able to differenti-
ate into adipocytes, osteocytes, chondrocytes, hepatocytes, neurons and cardiomy-
ocytes [29]. ASC are easily obtained through lipoaspiration or abdominoplasty, both
minimally invasive procedures compared to MSC harvesting from bone marrow [28].
In a study conducted by Harris, et.al, it was shown that advanced age (greater than
70 years), gender, BMI, diabetes mellitus, and peripheral vascular disease did not
significantly affect ASC density in the fat tissue [30]. For many of these reasons, ASC
are gaining more attention in the areas of tissue engineering and cell therapy.
1.4.1 ASC Support Formation of Robust Vascular Networks When Co-
seeded With EC
Traktuev, et.al. found that while cord blood-derived Endothelial Cells (EC) were
sufficient to form functional vessels in mice, the vessels were limited in number and
persistence [27]. When the EC were co-seeded together with ASC in vitro and in
in vivo collagen implants, ASC were found to function in a pericytic manner by
surrounding and stabilizing functional microvessel networks formed by EC. ASC not
only increased stability but also the number of functional vessels formed by EC [27].
8The ASC exerted their effect via direct contact and by secretion of various angiogenic
and anti-apoptotic factors [31,32].
1.5 ASC Promote Keratinocyte Survival and Wound Closure
ASC have been shown to possess therapeutic potential in the healing of cuta-
neous wounds. In previous studies done in our lab, Blanton et. al. found that
while ASC+plasma (either platelet rich or platelet poor) delivered in a fibrin gel to
full-thickness wounds in pigs did not show an increase in wound closure rate, com-
pared to saline control, both types of plasma vehicles containing ASC, stimulated an
increase in vascular density in their respective wound beds [33]. However the combi-
nation of platelet-rich plasma (PRP) with ASC showed the greatest improvement in
wound cosmesis. Increased VEGF accumulation in the wound bed was observed in
all treatments containing ASC. The lack of observed effect on re-epithelialization was
attributed to the fact that improving healing in normal, healthy, skin is often difficult
to observe. This study was further extended by Hadad et. al., who found that ASC +
platelet-rich plasma delivered in a fibrin gel to full-thickness wounds in an irradiated
(delayed wound healing) porcine model, showed an increase in microvessel density
and in wound closure rate compared to saline control [34].
The incidence of cutaneous wounds, such as foot ulcers, is on the rise due to an
increased incidence of diabetes. Amos, et.al showed that ASC applied to full-thickness
wounds in a diabetic mouse model (leptin receptor deficient db/db mice) significantly
improved healing compared to diabetic control. ASC were delivered as multicellular
aggregates [35].
Nie, et.al, showed that ASC administered locally via intradermal injections to a
full-thickness cutaneous wound resulted in faster wound closure in both normal and
diabetic mice. It was found that in the wound site there was an increase in the pro-
angiogenic cytokines HGF and VEGF in ASC treated wounds. They also saw evidence
of ASC incorporation into regenerated epidermal structures and differentiation into
9vascular structures [36]. Nie, et.al. also showed that ASC delivered to the site of
excisional wounds in diabetic rats using Acellular Dermal Matrix (ADM), increased
wound closure rate via increased epithelialization and tissue regeneration. There
was also increased capillary density and increased expression of angiogenic factors in
wounds receiving ASC-ADM grafts compared to controls [37].
Kim et.al. showed that the application of ASC to cutaneous wounds in nude mice
increased epithelialization, compared to control, via ASC stimulated proliferation of
human dermal fibroblasts by direct cell-cell contact and by paracrine activity [38,39].
ASC conditioned media was shown to promote increased proliferation and survival
of HaCaT cells (immortalized keratinocytes) and primary dermal fibroblasts and to
increase migration of HaCaT cells in a scratch assay [40].
Overall, the data of the literature suggests that ASC are able to promote healing
in both porcine and murine wound healing models and have a positive effect on re-
epithelialization. While work has been done to apply ASC to cutaneous wounds to
promote wound healing, thus far, it is a novel concept to deliver both ASC and EC
to the site of injury via an acellular wound healing scaffold. Since Integra is already
indicated for use in third degree burn wounds, investigating whether delivery of ASC
or ASC+EC on Integra enhances its healing capabilities is a worthwhile study, and
could set the stage for practical clinical applications in the near future.
1.6 Spray Delivery of Cells
As mentioned above, CEA is one approach to skin grafting, and involves taking the
available (often small) areas of skin, removing a biopsy, and expanding the patient’s
cells into sheets of keratinocytes that can then be applied to the wound to provide
coverage [14, 24]. However, the length of time required to prepare these sheets of
keratinocytes (2-3 weeks), susceptibility to infection, and fragility has made them
unsuitable in many cases [41–44]. As such, alternative mechanisms have been sought.
The ReCell R© spray device is a novel adaptation of the normal CEA application.
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Instead of waiting days to weeks to deliver sheets of cells, keratinocytes are harvested
from skin biopsies and sprayed over a much larger surface area. These cells which are
isolated from the dermal-epidermal junction, are highly proliferative and thus assist
with a faster healing rate [41].
This method of delivery may also be a useful way to apply other cell types to
wounds.
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2. HYPOTHESIS AND AIMS
Based on the literature review of the data previously published by our and other
groups, and on our preliminary findings, we devised two hypotheses:
(1) Human ASC, by their paracrine activity, will promote
revascularization of dermal matrices by the host, and accelerate wound
closure (compared to control), when applied to full-thickness wounds.
and
(2) Co-seeding EC with ASC on dermal matrices will facilitate and
enhance EC re-organization into vascular networks and thus improve
graft revascularization and overall graft retention and wound closure.
In order to test the hypotheses, the following aims were developed:
1. To assess if ASC promote survival of EC and their reorganization into stable
microvessel networks when these two cell types are co-seeded onto scaffolds.
2. To assess the response of keratinocytes to factors secreted by ASC and ASC+EC.
3. To determine whether transplantation of the dermal matrices pre-seeded with
ASC or ASC+EC into acute murine full-thickness wounds, will result in efficient
graft vascularization and promote wound closure, when compared with effect of
intact grafts containing no cells.
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3. METHODS
All procedures for collecting human tissues (umbilical cord and adipose tissue) were
approved by the Indiana University School of Medicine Institutional Review Board.
3.1 Isolation and Culture of ASC, EC and Keratinocytes
Human adipose stromal cells (ASC) were isolated from human subcutaneous adi-
pose tissue samples obtained from liposuction procedures. Briefly, samples were di-
gested in 1 mg/ml of collagenase type I solution (Worthington Biochemical, Lake-
wood, NJ) under agitation for one hour at 37◦C, and then centrifuged at 300g for
eight minutes to separate the stromal cell fraction (pellet) from adipocytes. The pel-
lets were filtered through 250 µm Nitex filters (Sefar America Inc., Kansas City, MO)
and treated with red cell lysis buffer (154mM NH4Cl, 10mM KHCO3, and 0.1mM
EDTA). The final pellet, also called SVF, was re-suspended and cultured in EGM-
2mv (Lonza, Walkersville, MD). Media was changed after first 24 hours, and then
every 3-4 days. Monolayers of ASC were passaged when 60-80% confluent and used
at passages 3-6. Purity of ASC samples from endothelial cells was confirmed by
staining of ASC monolayers with anti-CD31 antibodies.
Cord blood-derived endothelial cells (EC) were isolated from the umbilical cord
vein blood of healthy newborns (38-40 weeks gestational age). Mononuclear cells
were isolated from blood samples by gradient centrifugation through Histopaque 1077
(ICN, Costa Mesa, CA), followed by culturing in EGM-2/10% FBS (Lonza) media
in six well tissue culture plates (50 × 106 cells/well) pre-coated with 50 µg/ml of
type I rat tail collagen (BD Biosciences, San Diego, CA). The culture medium was
changed daily for seven days, and then every other day until first passage. Confluent
EC were re-plated into flasks coated with rat tail collagen type I, and cultured in
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EGM-2/10%FBS medium. Cells were passaged after becoming 90% confluent and
used at passages 6-13.
Neonatal Normal Human Epidermal Keratinocytes (NHEK) were obtained from
Lonza and grown in KGM-Gold media (Lonza). Cells were passaged after becoming
75%-90% confluent and used at passages 3-6.
ASC (60×103/cm2) and EC (10×103/cm2) were pre-mixed and plated on culture
plastic. Cells were cultured in DMEM/F12 supplemented with 1% BSA for six days,
with media change at day three.
3.2 Transduction of ASC and EC with GFP and DsRed Encoding Lentivi-
ral Constructs
ASC were plated in T-25 flasks at a density of 1× 104 cells/cm2 in EGM-2mv and
EC in T-25 flasks at a density of 2× 104 cells/cm2 in EGM-2/10% FBS. In three hours
post plating, media on cell monolayers were exchanged for fresh one supplemented
with 8 µg/ml of polybrene and 10% (by volume) of pCSCGW-DsRed2 lentiviral
stock solution or 2% (by volume) of pCSCGW-EGFP lentiviral stock solution. The
next day, the transduction solution was removed and replaced with fresh culture
media. The cells were expanded and then sorted using FACS Aria Sorter. Cells with
extremely high and very low expressions of fluorescent protein were discarded, and
cells with a median fluorescent protein expression were collected for expansion. Non-
transduced ASC and EC were used during sorting procedure to establish cutoff for
autofluorescence. After sorting, cells were replated for expansion.
3.3 EC, ASC and ASC+EC Cultivation on Integra and Alloderm Scaf-
folds
GFP-expressing ASC and DsRed-expressing EC were seeded onto 1 cm2 rectan-
gular pieces of Integra (Integra LifeSciences, Plainsboro, NJ) and Alloderm (Lifecell
Corporation, Branchburg, NJ) in EBM-2/5%FBS/1%penicillin/streptomycin. Inte-
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gra is a bovine-derived, collagen-based matrix with a silicone backing. The matrix
serves as the ”dermal” side and the silicone backing serves as the ”epidermal” side.
The silicone backing prevents moisture loss and provides a barrier to pathogens. Al-
loderm is decellularized, freeze-dried human dermis. It also has a shiny, smooth,
white dermal side and a rough, dull, buff-colored basement membrane side. In both
scaffolds, cells were seeded on the dermal side.
In the experiment there were three groups with n = 3 in each one: (1) ASC alone
(105 cells/cm2, P5); EC alone (105 cells/cm2, P10); (3) co-culture with 105 cells/cm2
ASC + 105 cells/cm2 EC.
Integra and Alloderm were cut to fit into the chambers of 8-well glass slides (BD
Biosciences, MA). Cells were seeded on scaffolds in 100 µl of EBM-2/5%FBS/
1% penicillin/streptomycin, and allowed to attach overnight. The next day, the scaf-
folds were transferred to non tissue culture treated 24-well plates (Corning Inc, NY)
in media, with side on which cells were seeded, facing up. They were maintained in
these 24-well plates for the duration of the experiment.
To monitor cell survival and their reorganization into microvessels, images of
mono- and co-cultures on Alloderm and Integra were taken every day with a Nikon
Eclipse Ti microscope with channels appropriate for detection of GFP and DsRed
fluorescent proteins.
3.4 Generation of Conditioned Media By ASC and ASC+EC Cultures
When Plated on Tissue Culture Plastic
To generate conditioned media from ASC and ASC+EC co-cultures, three dif-
ferent ASC samples at passages 2 and 3 and one sample of EC at passage 10 were
used. ASC alone from each donor (6 × 104 cells/cm2) and ASC + EC (6 × 104
cells/cm2 of ASC and 104 cells/cm2 of EC) were seeded into T-25 flasks in 4.5 ml
of DMEM/F12/5% FBS. Cells were allowed to attach for a few hours and then the
media was exchanged for DMEM/F12/1%BSA for overnight incubation. The next
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day, media was replaced with fresh DMEM/F12/1%BSA and cells were incubated for
72 hours. At the end of the incubation period, the media was collected, spun down to
remove debris and dead/floating cells, aliquoted, and stored at −80◦C. The outcome
was six different conditioned media samples (three from ASC alone and three from
ASC+EC, each from three different ASC donors). These media were used to test
keratinocyte survival and migration.
3.5 Generation of Conditioned Media By ASC and ASC+EC When Cul-
tured On Integra and Alloderm
ASC and EC were seeded onto 1 cm2 pieces of Integra and Alloderm in EBM-
2/5%FBS/1%penicillin/streptomycin. There were two groups: ASC alone (105/cm2)
and co-culture of ASC (105/cm2) with EC (105/cm2). Three different ASC samples
were used, as described above. The outcome was six different sets of conditioned
media (three from ASC alone and three from the same three ASC samples, each
combined with EC from the same donor). Conditioned media was collected every
day, spun down to remove cellular debris, and frozen for future evaluation.
3.6 Evaluation of Effects of ASC and ASC+EC Conditioned Media on
Keratinocyte Survival
Keratinocytes were seeded in KGM-Gold growth medium at 25 × 103 cells/cm2
into 24-well plates. The next day, the medium was switched to DMEM/F12/1%BSA
and cells were incubated overnight. After that, cells were exposed to ASC or ASC+EC
conditioned media (diluted 1:1 with fresh DMEM/F12/1% BSA) for six days with a
media change at day three. The control medium consisted of DMEM/F12/1%BSA.
After six days, the keratinocytes were fixed in cold methanol and stained with eosin.
From each well, nine images were taken at 20x magnification. The areas covered by
cells in each image were quantified using Nikon Elements software (Nikon, Melville,
NY).
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3.7 Evaluation of Effects of ASC and ASC+EC Conditioned Media on
Keratinocyte Migration
Strips of parafilm were cut, rinsed in 70% ethanol, allowed to dry and then pressed
to the bottom of wells of a 24 well plate, along the center. Keratinocytes were seeded
in their growth medium over the parafilm strips at 15 × 104 cells/cm2 overnight, after
which the growth medium was replaced with DMEM/F12/1%BSA for 24 hour incu-
bation. The next day, the strips of parafilm were removed, leaving a thin cell-free gap.
ASC or ASC+EC conditioned media was mixed 1:1 with fresh DMEM/F12/1%BSA
and applied to cells (n=4). Gaps formed after parafilm strip removal were pho-
tographed; the cells were incubated for 48 hours in the conditioned media, then fixed
with cold methanol and the gaps photographed again. Control wells were incubated
with DMEM/F12/1%BSA. Image J (NIH) was used to trace and measure the change
in the gap area from t = 0 to t = 48 hrs.
3.8 Preparation of Integra Scaffold For Implantation
Integra scaffolds were cut into circular discs using an 8 mm biopsy punch tool
(Acuderm, Fort Lauderdale, FL). With a thickness of 0.1 cm and radius of 0.4 cm,
the total volume of each scaffold was calculated as: 0.05 cm3. Non-transduced ASC
and DsRed expressing EC were seeded onto the dermal side of the scaffolds at a
concentration of 10 × 106 cells/cm3 (500,000 cells/scaffold). Cells were seeded onto
the scaffold the day before implantation. Integra scaffolds were seeded with: (1) ASC
alone (50 × 104 cells/scaffold), (2) ASC+EC (25 × 104 ASC + 25 × 104 EC). Control
consisted of Integra scaffolds (no cells seeded) soaked in DMEM/F12/1%BSA.
3.9 Mouse Full-Thickness Wound Model
Animal studies were approved by the Institutional Animal Care and Use Commit-
tee of Indiana University. In the model, NOD/scid/IL2Rgnull (NSG) mice were used.
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Wounds were made down thru the panniculus carnosus with an Acuderm biopsy punch
tool (Acuderm) and then cut out using an Iris scissor. Integra scaffolds were prepared
and incubated overnight as described above. The next day, they were pushed through
the wound window and positioned cell side up at the center of the wound window
as much as possible. Tegaderm (3M, St. Paul, MN) was used to cover the wounds
to keep them from drying out and to protect them from bacterial contamination. It
also served as a splint to inhibit wound contraction. To reinforce the Tegaderm and
prevent the mice from removing it and disturbing the wounds, mice were bandaged
with Vetrap (3M, St. Paul, MN). Mice were checked daily to ensure that the ban-
dages stayed in place. If necessary, mouse was rebandaged. Mice were kept under
1.5% isoflurane gas anesthesia during surgery, during scaffold implantation, and each
time wounds were imaged.
3.10 Power Analysis On Pilot Mouse Study Data
A pilot experiment was performed in anticipation of the full animal study. Data
from the pilot was used to generate a Monte Carlo based power analysis. In the
pilot study: (1) 5 male NSG mice were used, (2) Silicone backing was removed from
the Integra before placing in wound. (3) A 4 mm Acuderm biopsy punch tool was
used to make the wounds, (4) Experiment was stopped at Day 11, and (4) No cells
were seeded on scaffold (all controls). The 5 NSG mice were wounded as described
above. Discs of Integra scaffold (without cells) with the silicone backing removed,
were placed in the wound windows. The wound closure rate in these control mice
was used to perform a power estimation. The power estimation helped determine the
number of wounds needed in each treatment group and control, to detect a statistical
difference between control and treatment groups.
The statistical model used to perform this analysis is outlined below. It was
conducted by Michael G. Wilson, an independent biostatistician with Biostatistical
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Communications, Inc :
Y (i, j, k) = µ+ [β(i)× trtgrp(i)× day] + animal(i, j) + (i, j, k) (3.1)
Where:
i = 1, 2, or 3
j = 1, 2, , n
k = 1 or 2 (right or left)
n = number of animals per treatment group
µ = the overall intercept (mean)
trtgrp (i) denotes an indicator variable for the ith treatment
day is the numeric day of the measurement (one degree of freedom)
animal (i,j) is random variable and is distributed iid N(0, σ2(for animal))
β(i) denotes the slope of the ith treatment
 (i,j,k) is random error and is distributed iid N(0, σ2 (for error))
animal (i,j) and epsilon (i,j,k) are independent
The rate of healing at day 11 was used in the model (pilot). At this time point,
the average wound area was 7 mm2, and the slope was -1.27 mm2/day. Since no
treatment groups were analyzed in the pilot, their slopes were estimated for the
model. The assumption was made that ASC+EC would have a steeper slope than
ASC alone. ASC alone would have a steeper slope than the control. With that in
mind, the wound size for the ASC treatment group at Day 11 was estimated to be
about 5 mm2, which gave a slope of -1.45 mm2/day. The wound size for the ASC+EC
treatment group was estimated to be about 3 mm2 at day 11, giving a slope of -1.64
mm2/day.
The power was estimated using a Monte Carlo simulation using the control slope,
the estimated treatment slopes, and the correlational time structure (Toeplitz cor-
relation). Toeplitz refers to a matrix where every descending diagonal from left to
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right is constant. The study was simulated 10,000 times and then analyzed using the
mixed linear model outlined above.
3.11 Animal Study
Nine male and nine female NSG mice that were six weeks old were used in this
study. Scaffolds were prepared with ASC or ASC+EC, and wounds made as described
above, except that: (1) Silicone backing remained intact and was not removed from
the Integra before placing in wound. (2) A 3 mm Acuderm biopsy punch tool was
used to make the wounds, and (3) Experiment was stopped at Day 20. With silicone
layer still intact, cellular migration into scaffold from below the scaffold was inhibited.
At day 0, 7, 10 and 14, bandages were removed and images of the mouse wounds were
taken using a digital camera. A ruler was placed in each of the images to serve as a
scale. Images were analyzed using Image J to measure wound areas. At day 20, mice
were sacrificed and implants were harvested for histological analysis.
3.12 Statistical Analysis of Mouse Study
An ANCOVA Model with Main Effects with Multiplicative interaction was the
model used to test the primary hypothesis. The model, as outlined below, was built
by Michael G. Wilson. While the ANCOVA model used here is different than the
one used in the power estimate, the two models give similar conclusions (data not
shown) and this given model has the advantage of fitting the data better and being
less controversial, by generating fewer statistical comments. This was confirmed by
the corrected Akaike information criterion (AICC) numbers (578.5 vs. 586.7). These
numbers define the relative quality of a statistical model, and their difference is used
to determine the relative likelihood of two models, with a higher difference resulting
in a higher likelihood that the model with the smaller number fits the data best [45].
20
Y (i, j, k) = µ+β1(i)×trtgrp(i)+β2×day+[β3(i)×trtgrp(i)×day]+animal(i, j)+(i, j, k)
(3.2)
Where:
i = 1, 2, or 3
j = 1, 2, , n
k = 1 or 2 (right or left)
n = number of animals per treatment group
µ = the overall intercept (mean)
trtgrp (i) denotes an indicator variable for the ith treatment
day is the numeric day of the measurement (one degree of freedom)
animal (i,j) is random variable and is distributed iid N(0, σ2 (for animal))
β1 (i) denotes the effect of the ith treatment
β2 denotes the effect due to day
β3 (i) denotes the slope of the ith treatment
 (i,j,k) is random error and is distributed iid N(0, σ2 (for error))
animal (i,j) and epsilon (i,j,k) are independent
3.13 Immunohistochemical Analysis of Implanted Grafts
At 20 days, mice were sacrificed, and the scaffolds were removed with any attached
tissue. The Integra scaffolds were fixed in 10% formalin solution (Fisher Scientific,
Kalamazoo, MI), cut in half, paraffin embedded, and then sectioned. Slides were
Hematoxylin & Eosin (H&E) stained and examined for RBC containing vessels in
the scaffold. ASC+EC sections were also stained with mouse anti-human CD31 IgG
(Dako, Carpinteria, CA) to detect vessels formed by donor endothelial cells. Briefly,
tissue sections were incubated for 15 minutes with mouse anti-human CD31 (primary).
Next, tissue was incubated with a labeled polymer for 10 minutes. Finally, DAB
development was done for 10 minutes.
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3.14 Pilot experiments for future direction of project
3.14.1 Seeding keratinocytes with ASC and ASC+EC on Integra Scaffold
Keratinocytes were seeded alone, or with ASC, or with ASC+EC on disks (r =
4mm) of Integra scaffold in DMEM/F12/1%BSA. For this experiment, GFP-ASC
and DsRed-EC were used. Keratinocytes were labeled with DiD (Molecular Probes,
Eugene, OR) following the manufacturer protocol. Keratinocyte alone group was
seeded at 5× 104 cells/scaffold. 50× 104 ASC were mixed with 5× 104 keratinocytes
before seeding on scaffold for ASC+keratinocyte case. ASC+EC (25×104 cells each)
were mixed with 5× 104 keratinocytes before seeding on Integra. Images were taken
at Day 2.
3.14.2 Spraying Cells With ReCell R©
To test the feasibility of spraying ASC, EC and keratinocytes in anticipation of
a clinical study, keratinocytes, GFP-ASC and DsRed-EC were sprayed into a petri
dish using a ReCell R© Spray-On Skin kit (Avita Medical, CA), provided by Dr. R.
Sood. The petri dish was covered with a thin layer of DMEM/F12, 5% FBS. Feasi-
bility of successful delivery of ASC, EC, and keratinocytes via spray technology was
considered by comparing to the dripped case. Cell suspensions GFP-ASC+DsRed-
EC+unlabeled keratinocyte (7 × 104 each) were mixed, taken up with 5ml syringes
and either dripped from the syringe or sprayed by attaching the nozzle to the tip of
the syringe. After either spraying or dripping, cells were transferred to a 6 well plate.
Fifteen images were taken of each well at 10x using a Nikon Eclipse Ti camera. The
next day, cells were counted and number/unit area determined.
Freshly prepared SVF sample was resuspended in EGM2-mv. To prepare the
SVF for spraying, it was filtered again using a 40 µm filter. The cell suspension was
taken up by a syringe and sprayed with a ReCell R© spray nozzle, into a thin layer of
EBM-2/5%FBS in a petri dish. The cells were then transferred to a 48 well-plate.
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After six days, the SVF was fixed and stained for Lectin to detect vessel formation.
Briefly, cells were incubated with biotin labeled lectin (Vector labs, CA) for 1 hour,
and streptavidin elexa 488 (Vector labs, CA) for 30 minutes.
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4. RESULTS
4.1 ASC Promote Survival of EC and Stabilize Microvascular Networks
On Dermal Matrices
In order to determine if ASC stabilization of vascular endothelial networks (as
observed in collagen plugs and on tissue culture plastic by our lab [27,32] ) occurred
when the cells were seeded on dermal matrices, ASC alone, EC alone, or ASC+EC
cell mixture were seeded on rectangular pieces of Integra and Alloderm as described
in the Methods.
EC, when seeded alone onto dermal matrices, showed little survival after 7 days
(Figures 4.1 and 4.2). ASC, however, not only survived on Integra and Alloderm after
7 days, but also promoted survival of EC and the stabilization of vascular networks as
was previously observed. Merfeld-Clauss, et al. have shown evidence that ASC, via
paracrine mechanisms and cell-to-cell contact, stabilize the formation of microvessel
networks formed by EC [32]. We hypothesize that this is the likely mechanism of
microvessel formation on Integra and Alloderm.
Interestingly, it is observed that the microvessels formed on Alloderm seemed to
form on the surface of the scaffold, indicating that cellular penetration into Alloderm
was minimal. At the same time, microvessels formed on Integra appeared to have
more 3D organization, suggesting deeper penetration into the scaffold. Confocal
microscopy analysis was done to support this prior observation and to demonstrate
3D organization of the EC in the matrix (see Figure 4.3).
As has been discussed already, timely revascularization is critical for graft inte-
gration and overall patient recovery [26]. Thus, the rate of network formation by
ASC+EC co-cultures is of interest, as this will affect the rate of healing and of graft
integration. Figures 4.4 and 4.5 show the dynamics of EC organization into vascular
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networks during the 7 day period after plating on Integra and Alloderm, respectively.
By day 3 networks begin to form and by day 5, the vascular network is mostly orga-
nized.
(a) EC alone on Integra. (b) ASC alone on Integra.
(c) ASC+EC on Integra.
Fig. 4.1. ASC, EC, and ASC+EC survival on Integra. Representative
images of GFP-ASC (green) and DsRed-EC (red) seeded (a, b) alone
or in (c) mixture (1:1) onto Integra taken at day seven post plating
(n = 5).
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(a) EC alone on Alloderm. (b) ASC alone on Alloderm.
(c) ASC+EC on Alloderm.
Fig. 4.2. ASC, EC, and ASC+EC survival on Alloderm. Representa-
tive images of GFP-ASC (green) and DsRed-EC (red) seeded (a, b)
alone or in (c) mixture (1:1) onto Alloderm taken at day seven post
plating (n = 5).
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(a) View 1.
(b) View 2.
Fig. 4.3. Snapshots from confocal based movie clip showing (a) 3D
organization of ASC (green) and EC microvessels (red) on Integra and
(b) 100 µm depth of section.
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(a) Day 1, 40x. (b) Day 2, 40x. (c) Day 3, 40x.
(d) Day 4, 40x. (e) Day 5, 40x. (f) Day 6, 40x.
(g) Day 4, 100x. (h) Day 7, 100x. (i) Day 7, 200x.
Fig. 4.4. Dynamics of EC organization into microvessels on Integra,
when co-plated with ASC. We plated mixture of DsRed-EC and GFP-
ASC (1:1). Pictures were taken daily for 7 days using a Nikon Eclipse
Ti with appropriate channel for DsRed fluorescent protein (n = 3).
(a)-(f) Day 1-Day 6, 40x. (g) Day 4, 100x. (h) Day 7, 100x. (i) Day
7, 200x
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(a) Day 1, 40x. (b) Day 2, 40x. (c) Day 3, 40x.
(d) Day 4, 40x. (e) Day 5, 40x. (f) Day 6, 40x.
(g) Day 4, 100x. (h) Day 7, 100x. (i) Day 7, 200x.
Fig. 4.5. Dynamics of EC organization into microvessels on Alloderm,
when co-plated with ASC. We plated mixture of DsRed-EC and GFP-
ASC (1:1). Pictures were taken daily for 7 days using a Nikon Eclipse
Ti with appropriate channel for DsRed fluorescent protein (n = 3).
(a)-(f) Day 1-Day 6, 40x. (g) Day 4, 100x. (h) Day 7, 100x. (i) Day
7, 200x
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4.2 ASC and ASC+EC Conditioned Media (CM) Promotes Keratinocyte
Survival
Other studies have shown that ASC secrete paracrine factors that promote cell
survival [31,32]. Moreover, in this study we have shown their impact on EC survival
and the stabilization of vascular networks (Figures 4.1 and 4.2). Factors secreted
by ASC are also known to improve healing in cutaneous wounds in various animal
disease models [34,37–39]. With this in mind, we wanted to look at the effect of ASC
secretions on keratinocyte survival.
To investigate this, 72 hour ASC and ASC+EC conditioned media was collected as
described in the Methods section. The conditioned media was applied to sub-confluent
cultures of normal human epidermal keratinocytes. As shown in Figure 4.6(a), both
of these medias were able to increase survival of primary human keratinocytes by
about 2.5 times compared to control. There is always a concern with variability in
behavior of the cells obtained from different donors. However, our experiment has
shown that the media collected from three ASC samples has a significant positive
effect, with no differences observed between the samples (Figure 4.6(b)).
4.3 ASC and ASC+EC CM Promotes Migration Of Keratinocytes In
Cell In-Growth Assay
Noting ASC ability to promote faster healing of cutaneous wounds, we wanted
to investigate the effect of factors secreted by ASC on keratinocyte migration (as it
may be a possible mechanism of the enhanced wound closure previously observed
[34, 37–39]). To evaluate this effect, we used a wound closure assay as explained in
the methods section. After creating the gap in keratinocyte monolayer, the cells were
incubated in 50% of 72-hour ASC or ASC+EC conditioned media, diluted with fresh
DMEM/F12/1%BSA for 48 hours. The results (Figure 4.7(a)) indicated that the cell
migration rate into the gap was increased by 75% in response to both treatments
compared to control. This suggests that paracrine secretions may play a major role
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(a) Three ASC donor results combined. (b) ASC from three different donors.
Fig. 4.6. Media conditioned by ASC & ASC+EC promote survival of
keratinocytes. Keratinocytes were seeded at 25 x 103 cells/cm2 into
24 well plates. They were incubated in 50% ASC or ASC+EC con-
ditioned media (diluted with fresh DMEM/F12/1% BSA) for 6 days.
There were three different donor ASC samples tested, with an n of four
in each ASC and ASC+EC pair. After 6 days, the keratinocytes were
fixed in cold methanol and stained with eosin. From each well, nine
images were taken at 20x magnification. The area covered by cells in
each image was quantified using Nikon Elements software. (a). All
three donor ASC and ASC+EC results combined and compared to
control. (*** , p<0.001) (b). Keratinocyte survival in response to
each donor ASC and ASC+EC pair.
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(a) Three ASC donor results combined. (b) ASC from three different donors.
Fig. 4.7. Media conditioned by ASC and ASC+EC promotes mi-
gration of keratinocytes. Gaps formed in the midline of the wells
after parafilm strip removal, were photographed. At the end of 48
hours, the cells were fixed with cold methanol and photographed
again. There were three different donor ASC samples tested, with
an n of four in each ASC and ASC+EC pair. Image J (NIH) was
used to trace and measure the change in the gap area from t = 0 to t
= 48 hrs. (a). All three donor ASC and ASC+EC results combined
and compared to control. (***, p<0.001 (b). Keratinocyte migration
for each donor ASC and ASC+EC pair.
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in ASC-stimulated wound closure by promoting cellular migration. Once again, our
experiment has shown there is little variability between cells obtained from different
donors (Figure 4.7(b)).
4.4 ASC and EC Secrete Pro-Angiogenic Growth Factors When Seeded
On Dermal Matrices
ASC and ASC+EC conditioned media was shown to promote survival and migra-
tion of keratinocytes (Figures 4.6 and 4.7) and to promote survival and stabilization
of vascular networks formed by EC on Integra and Alloderm (Figure 4.1 and 4.2). The
conditioned media is composed of a variety of cytokines and growth factors. ELISA
was performed to evaluate the presence of two known pro-angiogenic factors, HGF
and VEGF, and to observe their daily accumulation in media conditioned by ASC
and ASC+EC seeded on Integra and Alloderm. To normalize for any differences in
cell-seeding number, values for day 1 were represented as 100%.
Analysis of conditioned media collected from Integra seeded with ASC+EC re-
vealed that the level of VEGF was significantly higher at day 3 for the mixed condi-
tion compared to ASC alone (Figure 4.8(a)). However, after this, the VEGF secretion
declines. By day 5 and day 6 there are significantly lower and lower amounts of VEGF
accumulating in the media for the ASC+EC case compared to ASC alone. In Fig-
ure 4.8(b), on Alloderm, the ASC and ASC+EC group reaches a steady, consistent,
daily accumulation of VEGF. The difference in VEGF accumulation on Alloderm vs.
Integra may be due to differences in the properties of the two dermal matrices.
HGF, another pro-angiogenic factor, shows a sharp downward trend in daily ac-
cumulation for ASC and ASC+EC groups on Integra betwen Day 1 and Day 3. After
this (Day 3-6), the secretion decline is a lot smaller (Figure 4.8(c)). Both ASC and
ASC+EC groups on Alloderm show a steady downward trend in HGF accumulation
(Figure 4.8(d)).
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(a) VEGF accumulation on Integra. (b) VEGF accumulation on Alloderm.
(c) HGF accumulation on Integra. (d) HGF accumulation on Alloderm.
Fig. 4.8. VEGF and HGF Accumulation by ASC and ASC+EC
seeded on Integra and Alloderm. ASC and ASC+EC (1:1) were seeded
onto Integra and Alloderm as previously described. Media was col-
lected every day and analyzed for accumulation of VEGF and HGF
via ELISA. (n = 3). (a). Accumulation of VEGF in the media condi-
tioned by ASC alone or by ASC+EC cell mixture when seeded onto
Integra. (b). Accumulation of VEGF in the media conditioned by
ASC alone or by ASC+EC cell mixture when seeded onto Alloderm.
(c). Accumulation of HGF in the media conditioned by ASC alone or
by ASC+EC cell mixture when seeded onto Integra. (d). Accumula-
tion of HGF in the media conditioned by ASC alone or by ASC+EC
cell mixture when seeded onto Alloderm.
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Fig. 4.9. Wound closure trend in five control mice. The average rate
of healing for all 10 wounds at day 11 was calculated (-1.27 mm2/day)
and used in the model. Bilateral wounds were made down thru the
panniculus carnosus with a 4 mm Acuderm biopsy punch tool on the
dorsum of 5 NSG mice, and then cut out using an Iris scissor. Inte-
gra with the silicone backing removed was placed in wound windown.
Wounds were covered with Tegaderm and bandaged with Vetrap. Im-
ages of the mouse wounds were taken at days 0, 8, and 11 using a
digital camera, and Image J was used to measure wound areas based
on the images.
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Fig. 4.10. Estimated Power to detect differences in wound area for
each treatment animal. In the model, the control ASC+EC group was
estimated to have the highest power overall with 12 wounds/group
giving a power of 80% compared to 40% for ASC alone group. The
power was estimated using a Monte Carlo simulation using the con-
trol slope, the estimated treatment slopes, and the correlational time
structure (Toeplitz correlation). Rate of healing at Day 11 was used in
the model outlined in Equation 3.1. In pilot, average rate of healing at
day 11 for the controls was -1.27 mm2/day. Based on our estimation,
the ASC group was modeled at -1.45 mm2/day and the ASC+EC at
-1.64 mm2/day.
36
4.5 Pilot Study Results Used To Generate Power Analysis For In Vivo
Experimental Design
With supporting in vitro work, the next step was to observe how ASC and
ASC+EC would influence healing in murine full-thickness wounds. Using the re-
sults from a pilot experiment (Figure 4.9) which investigated the wound closure rate
in 5 mice (2 wounds each) treated with Integra scaffold alone (no cell treatment),
a power analysis was performed. The goal was to determine a reasonable n for the
experimental study. The power analysis was estimated using a Monte Carlo simu-
lation (see Methods). The average rate of healing for all 10 wounds at day 11 was
calculated (-1.27 mm2/day) and used in the model. The rate of healing for ASC treat-
ment was estimated to improve by 15% more than control, at -1.45 mm2/day and
the ASC+EC treatment was estimated to improve by 30% at -1.64 mm2/day. The
ASC and ASC+EC treatment values were purely estimates based on speculation and
were not scientifically derived. With this in mind, we understand the limitations of
the model, but it provided a basis for informing the n of the experimental design in a
hypothetical case. Based on the experimental control slopes, the estimated treatment
slopes, and the correlational time structure (Toeplitz correlation) the graph for the
power estimate is seen in Figure 4.10. In the experimental design, we chose to use
12 wounds per treatment, which gave a power estimate of around 40% for the ASC
group vs. Control and around 80% for the ASC+EC group vs. Control.
4.6 Implantation Of Integra Pre-Seeded With ASC+EC Improves Rate
Of Wound Closure Compared To Integra Alone, In Cutaneous Full-
Thickness Wound Model
The pilot test served as the foundation of the full animal study. The experimental
design of the study is described in the Methods. In our current model, we began with
a total of 6 mice per group, which, with 2 wounds per mouse gave us 12 wounds per
mouse. However, due to a number of reasons which are listed, several wounds had
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to be discounted or could only be used for one or two time points. Final n used for
wound closure analysis at each time point:
Control: Day 7 (6), Day 10 (5), Day 14 (4) ASC: Day 7 (8), Day 10 (4), Day 14
(6) ASC-EC: Day 7 (6), Day 10 (4), Day 14 (5)
Wounds had to be excluded for the following reasons:
1. Wound contamination. White or greenish-yellow pus developed on a number
of wounds and reaction inhibited wound closure. The cause is unsure. In
some cases, a yellowish substance developed on the wounds and initially it was
thought this could be contamination, but the wounds progressed and closed as
expected, so it was ruled to likely be a fibrin exudate that is often released from
wounds.
2. Scaffold not found in mouse on day of sacrifice or found in a different location
than the wound window. There were several times that the mice removed their
bandages and tegaderm and had to be rebandaged. These are points where the
Integra scaffolds could have been removed.
3. Scaffold folded up in wound window, holding wound open.
4. Tegaderm not staying attached to wound under bandage.
5. One mouse died under anesthesia on Day 7 and three on Day 14.
However, even with the loss of so many data points, sufficient data was collected
to detect a statistically faster rate of wound closure for the ASC+EC treatment group
(Figure 4.11(a) using the ANCOVA statistical model (see Equation 3.2 in Methods).
However, ASC alone wound closure rate was not significantly different than control,
though it was faster (Figure 4.11(b).
The slopes for the control and treatment groups were approximated using best lin-
ear unbiased estimates (BLUE). Based on BLUE analysis, the slopes were calculated
to be -0.48 mm2/day for control, -0.93 mm2/day for ASC treatment group and -1.03
mm2/day for ASC+EC treatment group. The BLUE for the difference between the
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(a) Wound Closure Rate in ASC + EC vs. Control.
(b) Wound Closure Rate in ASC alone treatment vs.
Control.
Fig. 4.11. Wound closure rate of murine, full-thickness cutaneous
wounds treated with (a) ASC or (b) ASC+EC on Integra, with Inte-
gra alone as a control. The ASC+EC treatment promoted a higher
rate of wound closure compared to the control. The BLUE for the
difference between the ASC+EC group and the Control group heal-
ing rates is -0.55 +/- 0.28 mm2/day (p = 0.017 <0.025, Bonferroni
Adjusted), which is statistically significant. Bilateral wounds were
made down thru the panniculus carnosus with a 3mm Acuderm biopsy
punch tool on the dorsum of 18 NSG mice (9 male, 9 female), and
then cut out using an Iris scissor. 6 mice received control (Integra
scaffold with no cell treatment), 6 received Integra+ASC and 6 re-
ceived Integra+ASC+EC. Wounds were covered with Tegaderm and
bandaged with Vetrap. Images of the mouse wounds were taken at
days 0, 7, 10, and 14 using a digital camera, and Image J was used to
measure wound areas based on the images.
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ASC treatment group and the Control healing rates is -0.45 +/- 0.22 mm2/day. The
p value was 0.041, which is not less than 0.025 and thus not statistically significant
(Bonferroni Adjusted). The BLUE for the difference between the ASC+EC group
and the Control group healing rates is -0.55 +/- 0.28 mm2/day (p = 0.017 <0.025,
Bonferroni Adjusted), which is statistically significant.
This result suggests that the ASC+EC cell combination, which forms vascu-
lar networks, is contributing to graft vascularization and leading to more rapid re-
epithelialization. An analysis of the histology confirmed this.
4.7 Presence of ASC and ASC+EC In Integra Graft Increases Revascu-
larization In Cutaneous Full-Thickness Wounds
Noting the improved rate of wound healing for the ASC+EC treatment group, the
histology was analyzed to look for differences between the treatments. The number
of vessels was quantified (Figure 4.12) and revealed that ASC and ASC+EC treat-
ment both stimulated increased vascularization compared to control (Integra scaffold
alone). While there was no statistical difference in the number of vessels in ASC and
ASC+EC treatment scaffolds, ASC+EC treatment had a higher number of vessels.
4.8 Supplementary Results
4.8.1 Seeding Three Cell Types on Integra
Apligraf and Orcel are two commercially available wound healing scaffolds that
are seeded with keratinocytes before being applied to wounds [14, 20]. Noting their
importance in the wound healing process, this is no surprise. As a pilot study, we
investigated the possibility of seeding keratinocytes along with ASC+EC onto Integra
to deliver both revascularization and re-epithelialization potential to wounds. After
2 days, ASC, EC, and keratinocytes are present on the scaffold (Figure 4.14 as cap-
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Fig. 4.12. ASC and ASC+EC treated scaffolds are more highly vascu-
larized than the control scaffolds. Integra scaffolds seeded with ASC
and ASC+EC were placed in murine full-thickness wounds. At Day
20, grafts were harvested, fixed, sectioned, stained (H&E, hCD31)
and counted for mouse and human vessels. There were 10 sections of
tissue analyzed for each graft in 10 different regions of the scaffold.
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Fig. 4.13. hCD31 staining on ASC+EC treatment scaffolds reveals
vessels formed by human EC (brown)
42
tured through fluorescent microscopy. Delivery of all three cell types via Integra is a
consideration for future wound closure applications.
4.8.2 Feasibility of Spray Delivery of Cultured Cells and of SVF
ReCell R© Spray-On Skin (Avita Medical, CA) utilizes spray technology to deliver
keratinocytes to the site of debrided wounds. The process can be done at the bedside
and fosters an even distribution of cells over the area of interest, which allows a very
small skin biopsy to be used to cover a much larger area of skin. This has great
potential as a replacement for skin grafts in wounds, especially when large areas
of skin have been damaged. Dermal matrices such as Integra can be used to help
repopulate lost tissue volume and ReCell R© used to deliver the epidermal layer once
the graft has become vascularized. With this in mind, we wanted to evaluate whether
spray is a feasible method for delivery of ASC, EC and keratinocytes. In order to do
this, we used transduced GFP-ASC, DsRed-EC, and unstained keratinocytes. Figure
4.15 shows images of sprayed vs. dripped cells. These images were formed by merging
GFP (ASC) image, DsRed (EC) image and light microscope image (keratinocytes).
Figure 4.16 shows a quantification of surviving cells determined by taking nine 20x
images of each well and dividing cell counts by the area covered by each image. It
does not appear that there is a relevant difference in cell survival between the two
methods.
Based on our observation that ASC+EC promote an improvement in wound clo-
sure rate, and that they appear unaffected by being pushed through the Recell R©
nozzle, we wanted to assess the feasibility of delivering SVF via Recell R©. SVF is
attractive because it can be delivered at the bedside, and has all of the components
necessary to form microvessels. Lectin staining revealed that spraying does not appear
to affect SVF’s vessel-forming capability (Figure 4.17).
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(a) Endothelial Cells. (b) Keratinocytes.
(c) ASC. (d) Three images merged.
Fig. 4.14. Three cell types on Integra scaffold (10x). (a) DsRed-EC,
red, (b) DiD stained Keratinocytes, digitally colored blue, and (c)
GFP-ASC, green were seeded onto Integra scaffold. (d) At day 2,
representative images were taken (10x) and merged.
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(a) Sprayed cells.
(b) Dripped cells.
Fig. 4.15. Cultured cells (a) sprayed with ReCell R© vs. (b) dripped.
Cell survival was not diminished by spraying. Equal numbers of ker-
atinocytes (unlabeled), GFP-ASCs (green) and DsRed-ECs (red) were
mixed and sprayed using ReCell R© spray nozzle or dripped using a sy-
ringe and transferred to a 6 well plate. The next day, nine 20x images
of the wells were taken and cell number quantified. Images formed by
merging GFP (ASC) image, DsRed (EC) image and light microscope
image (keratinocytes unstained).
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Fig. 4.16. Cultured cells sprayed and dripped together. Cell survival
was not significantly diminished by spraying. Keratinocytes (unla-
beled), GFP-ASCs and DsRed-ECs were mixed and sprayed using
ReCell R© spray nozzle or dripped using a syringe and transferred to
a 6 well plate. The next day, nine 20x images of the wells were taken
and cell survival quantified.
Fig. 4.17. Spraying SVF using ReCell R© does not affect its ability to
form microvessels. Sprayed SVF is stained after 6 days for lectin (10x
image)
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5. DISCUSSION
This study aimed to evaluate the potential of using ASC alone and ASC in com-
bination with EC to promote graft revascularization. We hypothesized that ASC
would promote revascularization of the dermal matrices by their paracrine activity.
We also hypothesized that the ASC+EC combination would enhance and facilitate
EC re-organization into vascular networks, thus improving graft revascularization.
Histology revealed that both ASC and ASC+EC treatment groups had significantly
more vessels in Integra scaffolds, compared to the control, though only ASC+EC case
showed an improved rate of wound closure (compared to the control).
While ASC as a singular cell type has shown much potential in the arena of wound
healing, the microvessel forming capabilities of ASC+EC when seeded on Integra is
compelling. Rapid formation of robust, intact microvessel networks in a graft could
enhance graft take and wound healing rate, especially in areas of low vascularity.
However, one of the caveats of the use of cord-blood derived EC is that they are
an allogeneic source, and thus will need to be HLA host/donor matched to reduce
the chance for immune rejection. These EC are highly proliferative and easy to
expand, so banking them for cell delivery applications is very feasible. Additionally,
ASC have been shown to have immunosuppressive and anti-inflammatory properties
[46,47]. Thus, we speculate that delivery of EC along with ASC may alter the immune
response elicited by ECs’ allogeneic origins.
With 1 million burn injuries reported annually [12–14] and 45,000 hospitaliza-
tions due to fires and burns, the importance of having an effective treatment for
severe second-degree and third-degree burn wounds is critical. Skin grafts are a cur-
rent treatment for these types of wounds [16, 18], but there are several drawbacks
associated with their use including a lack of availability of suitable donor sites for
autografts in some instances, rejection and possible transfer of infection associated
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with allografts and xenografts, and poor graft retention due to infection, hematoma
and low vascularity at the recipient site. As such, research has been done into the use
of artificial skin substitutes as a burn treatment. They are readily available, encour-
age in-growth of surrounding cells, and can be loaded with specialized cells or growth
factors that stimulate faster healing, prevent fluid loss, and reduce scarring [17,20,21].
Skin substitutes can be subdivided into three major categories, including acellular,
cellular and cellular autologous [20]. Integra and Alloderm are acellular skin substi-
tute, indicated for use in a wide array of wound healing applications including burn
wounds. We successfully cultured ASC and ASC+EC on these scaffolds.
In an effort to preserve the integrity of the Integra matrix, and to mimic its clinical
use as closely as possible, we did not remove the silicone backing before implanting
them into the mouse full-thickness wounds. When Integra is used in clinic, the silicone
layer is only removed after the scaffold has successfully integrated with the host, and
is ready for application of a thin epidermal autograft [48]. The silicone layer serves as
a barrier to pathogens and helps retain moisture. In our model, the Integra scaffolds
were placed in the wound, with silicone side down, and dermal side facing up. While
perhaps not the ideal setup for a mouse wound healing model, this was done to
mimic clinical applications of Integra as much as possible. This means that host
vascularization and cellular in-growth was inhibited from below and limited to lateral
and top-side penetration.
Noting the vessel forming dynamics of EC in the presence of ASC, when cultured
on Integra and Alloderm, we speculate on the possibility of generating scaffolds with
pre-formed microvessel networks and applying these to wounds. This is an area
that needs further exploration. Perhaps there is an advantage to delivering intact
vascular networks to the site of wounds. On the other hand, effective microvessel
formation and integration with host may be a factor of ASC and EC interactions
with their environment as they are forming vessels. In this same vein, we considered
the possibility of using fluid flow to control the orientation of the networks. Vessel
orientation may be another factor that may enhance graft revascularization via host.
48
Perhaps vessels all oriented parallel or all at right angles to the site of injury, rather
than randomly, will integrate more easily with host vasculature. Much work was done
to generate flow-oriented microvessel networks on tissue culture plastic (See summary
in the Appendix). While largely unrepeatable, the results are presented here as they
may offer a framework for continuing this work and expanding it to a 3D model.
Initial experiments done with ASC and ASC+EC conditioned media also revealed
that their secreted factors increased survival and migration of keratinocytes. Ker-
atinocytes form the outer layers of epidermis and thus play an important role in the
wound healing process. It’s noteworthy that both ASC and ASC+EC conditioned
media had similar migratory and survival effects on keratinocytes. It suggests that
by 72 hours (length of incubation to generate conditioned media) there are no signifi-
cant differences in accumulation of critical factors. For the VEGF secretion profile on
Integra (Figure 4.8(a)), major changes in accumulation only occurred after 72 hours.
The murine model used to study wound closure had some limitations. There are
several structural and physiological differences in the skin and in the wound healing
process of mice vs. humans. One of these is the tendency of mouse wounds to heal
primarily via contraction and less via re-epithelialization. Galiano et. al. attempted
to address this limitation through the use of silicone disks sutured around the wound
site as a splint [49], but we found this method difficult to apply to our model. Instead,
we used tegaderm as a splinting material as has been done in a previous study [50].
In a brief experiment we performed (results not shown), we confirmed that tegaderm
splinted wounds had a significantly decreased rate of wound healing compared to
unsplinted wounds, most likely due to a reduction in wound contraction. During
the study, mice had to be monitored daily to ensure that they did not remove their
bandages and the underlying tegaderm. If the bandages were removed, mice were
placed under anesthesia and the bandages reapplied.
In spite of some of the limitations of our model, it is very promising that even in
this healthy murine model with normal skin, the ASC+EC treatment group showed
a statistically significant increase in wound closure rate and greater amount of vas-
49
cularity in the Integra scaffold compared to the cell-free control. We would expect to
see an even greater enhancement in a delayed wound-healing model. Study of such a
model would serve to validate our findings and provide opportunity for further study
of the mechanism of improved wound healing in ASC + EC treatment delivered via
Integra. An irradiated porcine model as described by Hadad, et. al. [34] would be
an excellent next step due to (1) the physiological and wound healing similarities
between porcine skin and human skin and (2) the impaired wound healing caused in
large part by a reduction in vascular perfusion due radiation exposure.
ASC+EC on Integra could be a possible treatment for full-thickness burn wounds
where application of a skin graft is unsuitable or in regions of low vascularity. Integra
is already indicated for use in third degree burns and delivery of autologous ASC and
readily available allogeneic EC to the site of the wound may prove efficacious due
to their vessel forming capabilities. It is well documented that poor vascularization
is a major contributor to graft failure, and that restoration of vascular perfusion is
critical in the wound healing process.
5.1 Future Direction
Based on the findings presented in the supplementary results, three ideas can be
further explored. First, spray technology as a delivery mechanism for keratinocytes
may be used in place of a skin graft in wounds treated with a dermal template, such
as Integra. Normally, after Integra becomes adequately vascularized, the silicone
backing is removed and a thin epidermal graft is applied for re-epithelialization. In
the case of burn wounds, if suitable donor skin availability is low due to extensive
burning, a small biopsy of skin can be taken and spray delivered to improve coverage.
Second, an alternative worth exploring is the delivery of ASC and ASC+EC in
combination with keratinocytes on Integra scaffold in a one-step application. We
have shown that seeding ASC+ EC+ keratinocytes on Integra is feasible. This may
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not only enhance vascularization (ASC or ASC+EC) but also re-epithelialization
(keratinocytes) and may remove the need for a second-step skin graft application.
Finally, the use of SVF in place of expanded and cultured ASC and ASC+EC
should be explored since it cuts down on time for expansion and isolation of pure
ASC and EC populations and can be delivered within hours of obtaining adipose
tissue from a patient.
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APPENDIX: USE OF FLOW-GENERATED SHEAR 
STRESS TO CONTROL ORIENTATION OF 
MICROVESSEL NETWORKS
A.1 Author’s Note
Looking at using shear stress generated by laminar fluid flow to align ASC-EC
microvessels was the project I first started out with. However, I quickly ran into
difficulties with contamination and then reproducibility. I attempted to find a flow
chamber that would allow me to successfully perform long-term flow analysis (3-6
days) while maintaining sterility. Then, once I got my hands on such a machine
(Cellmax Flow pump with ibidi cell culture chambers), I was able to observe ASC
alignment once, but could not reproduce it with the same or other donor ASC. It
seemed this project was destined to be a challenge from the start. In the end, after
many months of investigating new flow pumps and new strategies we switched to a
much simpler model, using an orbital shaker, and were able to reproduce the outcome
of flow aligned ASCs. However, there still remains a high degree of variability in the
outcomes. In conclusion, we were able to demonstrate the alignment of microvessels
formed by seeding ECs on flow aligned ASCs. Overall, this project reached a tem-
porary hold in favor of the wound healing project, but are interestingly linked as we
consider the possibility of generating pre-aligned vessel networks and applying these
to wounds.
A.2 Hypothesis
We hypothesized that due to its physiological influence, fluid shear stress may
have an effect on microvessel formation in vitro, impacting amongst other factors,
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microvessel network orientation. With this in mind, the first aim was to determine if
fluid flow could be used to control ASC orientation.
This work could have application in tissue engineering. The ability to control the
structure and orientation of vessels could be useful when attempting to grow organs
out of the body for implantation purposes.
A.3 Methods and Results
The basic experimental design was to seed ASC, EC and ASC+EC co-cultures
confluently onto the slide or flow area, allow them to attach overnight and then apply
shear stress.
Several different systems were investigated for studying fluid flow on ASC and
ASC+EC. All worked on the same basic premise of using a pump to move fluid from
a reservoir thru the cell chamber where the cells were grown, and could experience the
shearing force. The microfluid device used a vacuum to attach the flow chamber to a
petri dish (Figure A.1). Cells were seeded into a small rectangular area where fluid
was made to pass using a roller pump. The device was housed in a 5% Carbon dioxide
incubator to maintain ambient temperatures and pH. The second flow chamber used
differences in height and a roller pump to move fluid into the cell chamber (Figure
A.2). The cells were seeded onto glass slides and the slides inserted into the cell
chamber, which contained openings to allow media to flow over the cells, generating a
shear stress. The height of the reservoir could be adjusted to control the shear stress.
Unfortunately, none of these systems were designed for long-term culture and
I had great difficulties running the experiment for more than a day or two before
contamination set in. No alignment was observed in these experiments.
The third system we worked with was designed for long-term culture under flow.
It was a demo device we got to use for a month, obtained from Ibidi. They had special
culture slides that allowed cells to be grown as a monolayer, and media passed over
them via a pump system, to generate the shear stress. I had little success with the
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Fig. A.1. Microfluid flow device set-up.
Fig. A.2. Cell chamber used in laminar flow system developed by Dr.
Ji’s reasearch team in Engineering
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ibidi pump system before the demo period was up, but I learned how to use the slides
more effectively. In the fourth system, I used a flow pump developed by CellMax to
generate the shear stress, and used the ibidi slides to culture the cells. It was in this
system that I was first able to capture ASC alignment over a 6-day period (Figure
A.3). GFP-labeled ASC were allowed to attach overnight and then flow was applied
the next day. Images were taken with a Nikon Ti. Change in angle of orientation of
cells was measured using Image J (Figure A.4).
(a) Day 0 (b) Day 1 (c) Day 2
(d) Day 3 (e) Day 6
Fig. A.3. GFP-labeled ASC seeded into ibidi chamber and aligned
using shear stress over a 6 day period.
Unfortunately, I was never able to reproduce this result using the Cellmax flow
pump system, which raised a number of questions about conditions necessary for
ASC alignment. Additional ASCs were put under shear stress, but no alignment was
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Fig. A.4. Change in orientation angle of ASC over 6 day period of exposure to flow
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observed. This raised further questions about ASC response to shear stress. Perhaps
the initial outcome was an artifact due to over-culturing or some other phenomenon.
The next thing we attempted was very simple and was where we likely should have
started. We used an orbital shaker to generate shear stress on the cells, by seeding
them onto petri dishes and attaching them to the orbital shaker. Now, we had a
simple system to use and set-up with low incidence of contamination. The variable
shear stress along radius r, was initially why it was not chosen as the flow system of
choice. But, for achieving the aim of aligning microvessel networks, it proved useful.
However, the variability in ASC response continued. Many experiments were run
to test different donors, different ASC attachment times, different shear stresses and
different seeding densities, but nothing conclusive could be derived. Figure 20 shows
the most successful and promising outcome. It was set up as follows: 60k/cm2 ASC
seeded, allowed 3 hours to attach and then put under rotational flow for 4 days. At
the end of this, 10k/cm2 EPC were added and incubated for 6 days in EBM-2, 5%
FBS (static). DsRed ECs were used. See the results in Figure A.5. The outcome is
that flow aligned ASCs can be used to control the orientation of resulting microvessel
networks.
Now that we know this is possible, future plans would be to attempt to apply this
to a 3D model using a porous scaffold. Further work must also be done to elucidate
the secrets of the ASC flow-response, which seems quite variable and unpredictable
at present.
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(a) 12noon position of circle (b) 3pm position of circle
(c) 6pm position of circle (d) 9pm position of circle
Fig. A.5. Flow aligned ASC produce flow aligned microvessels.
